Expertise in
29
conditions

Dr. Abraham S. Kanate

Internal Medicine
Laja Treatment Center PLLC
10460 N 92nd St Ste 300, 
Scottsdale, AZ 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
18 Years of Experience
Expertise in
29
conditions
Laja Treatment Center PLLC
10460 N 92nd St Ste 300, 
Scottsdale, AZ 

Overview

Abraham Kanate is a primary care provider, practicing in Internal Medicine in Scottsdale, Arizona. He has been practicing medicine for over 18 years.

Dr. Kanate is highly rated in 29 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Myeloid Leukemia (AML), Bone Marrow Aspiration, and Colonoscopy.

He is actively involved in clinical research, co-authoring 68 peer reviewed articles and participating in 11 clinical trials. Dr. Kanate is currently accepting new patients.

Specialties

Internal Medicine

Licenses

Internal Medicine in WV

Hospital Affiliations

Honorhealth Scottsdale Shea Medical Center
Honorhealth Scottsdale Osborn Medical Center
Honor Health John C. Lincoln Medical Center

Languages Spoken

English
Hindi

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
MercyCare
  • EPO
  • HMO
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

Laja Treatment Center PLLC
10460 N 92nd St Ste 300, Scottsdale, AZ 85258
Other Locations
West Virginia University Hospitals
1 Medical Center Dr, Morgantown, WV 26506

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)
Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)
Enrollment Status: Recruiting
Publish Date: August 19, 2026
Intervention Type: Other, Biological, Drug
Study Drugs: Daratumumab, Dexamethasone, Lenalidomide
Study Phase: Phase 3
A Phase I Study With an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients With Relapsed/Refractory Hodgkin Lymphoma
A Phase I Study With an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients With Relapsed/Refractory Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: August 19, 2026
Intervention Type: Procedure, Drug, Biological
Study Drugs: Brentuximab, Ipilimumab, Nivolumab
Study Phase: Phase 1/Phase 2
A Phase I/II Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma
A Phase I/II Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma
Enrollment Status: Completed
Publish Date: June 25, 2026
Intervention Type: Drug
Study Drugs: Ixazomib, Ibrutinib
Study Phase: Phase 1/Phase 2
Intergroup Randomized Phase 2 Four Arm Study In Patients ≥ 60 With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB → R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV→ R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB → LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV → LR)
Intergroup Randomized Phase 2 Four Arm Study In Patients ≥ 60 With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB → R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV→ R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB → LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV → LR)
Enrollment Status: Active_not_recruiting
Publish Date: June 03, 2026
Intervention Type: Drug, Biological
Study Drugs: Rituximab, Bendamustine Hydrochloride, Bortezomib, Lenalidomide
Study Phase: Phase 2
S1803, Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients With Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
S1803, Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients With Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
Enrollment Status: Active_not_recruiting
Publish Date: September 15, 2025
Intervention Type: Drug
Study Drugs: Lenalidomide, Daratumumab/rHuPH20
Study Phase: Phase 3
Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2025
Intervention Type: Other, Drug
Study Drugs: Bortezomib, Carfilzomib, Dexamethasone, Lenalidomide
Study Phase: Phase 3
A Multicenter, Randomized, Open-label Phase 2 Study Evaluating the Safety and Efficacy of Three Different Regimens of Oral Panobinostat in Combination With Subcutaneous Bortezomib and Oral Dexamethasone in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma Who Have Been Previously Exposed to Immunomodulatory Agents
A Multicenter, Randomized, Open-label Phase 2 Study Evaluating the Safety and Efficacy of Three Different Regimens of Oral Panobinostat in Combination With Subcutaneous Bortezomib and Oral Dexamethasone in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma Who Have Been Previously Exposed to Immunomodulatory Agents
Enrollment Status: Completed
Publish Date: July 12, 2024
Intervention Type: Drug
Study Drugs: Panobinostat Capsules, Bortezomib Injection, Dexamethasone Tablets
Study Phase: Phase 2
A Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib vs. Pomalidomide and Dexamethasone for Patients With Multiple Myeloma Relapsing on Lenalidomide as Part of First Line Therapy
A Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib vs. Pomalidomide and Dexamethasone for Patients With Multiple Myeloma Relapsing on Lenalidomide as Part of First Line Therapy
Enrollment Status: Unknown
Publish Date: December 01, 2023
Intervention Type: Drug
Study Drugs: Pomalidomide, Ixazomib, Dexamethasone
Study Phase: Phase 1/Phase 2
A 3-Arm Randomized Phase II Trial of Bendamustine-Rituximab (BR) Followed by Rituximab vs Bortezomib-BR (BVR) Followed by Rituximab vs BR Followed by Lenalidomide/Rituximab in High Risk Follicular Lymphoma
A 3-Arm Randomized Phase II Trial of Bendamustine-Rituximab (BR) Followed by Rituximab vs Bortezomib-BR (BVR) Followed by Rituximab vs BR Followed by Lenalidomide/Rituximab in High Risk Follicular Lymphoma
Enrollment Status: Completed
Publish Date: June 29, 2023
Intervention Type: Drug, Biological
Study Drugs: Rituximab, Bendamustin, Bortezomib, Lenalidomide
Study Phase: Phase 2
Unrelated Umbilical Cord Blood (UCB) Transplantation
Unrelated Umbilical Cord Blood (UCB) Transplantation
Enrollment Status: Completed
Publish Date: June 14, 2021
Intervention Type: Genetic
Study Phase: Not Applicable
View 9 Less Clinical Trials

68 Total Publications

Reduced-Toxicity Conditioning Allogeneic Hematopoietic Cell Transplantation with Once-Daily Intravenous Busulfan for Relapsed/Refractory Lymphoma: A Phase II Study.
Reduced-Toxicity Conditioning Allogeneic Hematopoietic Cell Transplantation with Once-Daily Intravenous Busulfan for Relapsed/Refractory Lymphoma: A Phase II Study.
Journal: Transplantation and cellular therapy
Published: April 17, 2026
Similar Doctors
Expertise in
35
conditions
Dr. Mark E. Rose
Internal Medicine
Expertise in
35
conditions
Dr. Mark E. Rose
Internal Medicine

Office

13860 N Northsight Blvd, 
Scottsdale,, AZ 
 (2.3 miles away)
480-451-6756
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Mark Rose is a primary care provider, practicing in Internal Medicine in Scottsdale,, Arizona. Dr. Rose is highly rated in 35 conditions, according to our data. His clinical expertise encompasses Grass Allergy, Empyema, Sinusitis, and Allergic Rhinitis. Dr. Rose is currently accepting new patients.

Expertise in
6
conditions
Dr. Holly L. Geyer
Internal Medicine
Expertise in
6
conditions
Dr. Holly L. Geyer
Internal Medicine

Mayo Clinic Hospital In Arizona

5777 E Mayo Blvd, 
Phoenix, AZ 
 (6.9 miles away)
480-515-6296
Languages Spoken:
English
See accepted insurances

Holly Geyer is a primary care provider, practicing in Internal Medicine in Phoenix, Arizona. Dr. Geyer is highly rated in 6 conditions, according to our data. Her clinical expertise encompasses Myeloproliferative Neoplasms (MPN), Splenomegaly, Myelofibrosis, Bone Marrow Aspiration, and Colonoscopy.

Expertise in
12
conditions
Dr. Matthew A. Rank
Internal Medicine
Expertise in
12
conditions
Dr. Matthew A. Rank
Internal Medicine

Mayo Clinic Building Scottsdale

13400 E Shea Blvd, 
Scottsdale, AZ 
 (5.1 miles away)
480-301-4284
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Matthew Rank is a primary care provider, practicing in Internal Medicine in Scottsdale, Arizona. Dr. Rank is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Asthma, Sinusitis, Eosinophilic Esophagitis, Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), and Endoscopy. Dr. Rank is currently accepting new patients.

Frequently Asked Questions about Dr. Abraham S. Kanate

How do I make an appointment with Dr. Abraham S. Kanate?

You can book an appointment with Dr. Abraham S. Kanate by calling their office at 480-323-1573. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Abraham S. Kanate a top-rated expert for Non-Hodgkin Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Abraham S. Kanate is classified as an Distinguished expert for Non-Hodgkin Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Abraham S. Kanate specialize in?

While Dr. Abraham S. Kanate is a Internal Medicine, they have specific expertise in Non-Hodgkin Lymphoma, Multiple Myeloma, and Acute Myeloid Leukemia (AML). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. Abraham S. Kanate participate in research or clinical trials?

Yes. Dr. Abraham S. Kanate has published 68 articles and abstracts on conditions like Non-Hodgkin Lymphoma. You can view a list of Dr. Abraham S. Kanate's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Abraham S. Kanate accept my insurance?

Dr. Abraham S. Kanate accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 480-323-1573 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kanate's expertise for a condition
ConditionClose
    View All 10 Distinguished Conditions
    View All 19 Advanced Conditions
    View All 44 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile